Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Disrupting a converging metabolic target turns up the immunologic-heat in pancreatic tumors
Won Jin Ho, Elizabeth M. Jaffee
Won Jin Ho, Elizabeth M. Jaffee
Published December 3, 2019
Citation Information: J Clin Invest. 2020;130(1):71-73. https://doi.org/10.1172/JCI133685.
View: Text | PDF
Commentary

Disrupting a converging metabolic target turns up the immunologic-heat in pancreatic tumors

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinomas (PDACs) are classically immunologically cold tumors that have failed to demonstrate a significant response to immunotherapeutic strategies. This feature is attributed to both the immunosuppressive tumor microenvironment (TME) and limited immune cell access due to the surrounding stromal barrier, a histological hallmark of PDACs. In this issue of the JCI, Sharma et al. employ a broad glutamine antagonist, 6-diazo-5-oxo-l-norleucine (DON), to target a metabolic program that underlies both PDAC growth and hyaluronan production. Their findings describe an approach to converting the PDAC TME into a hot TME, thereby empowering immunotherapeutic strategies such as anti-PD1 therapy.

Authors

Won Jin Ho, Elizabeth M. Jaffee

×

Figure 1

Targeting a point of convergence in metabolic pathways in PDAC.

Options: View larger image (or click on image) Download as PowerPoint
Targeting a point of convergence in metabolic pathways in PDAC.
Glutamin...
Glutamine is involved as a substrate for the anaerobic metabolic processes whereby the tricarboxylic acid (TCA) cycle uses glucose to enable effective PDAC cell growth. Glutamine is also a substrate for the rate-limiting enzyme GFAT, which is part of the HBP that acts via uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) and leads to hyaluronan synthesis. Thus, glutamine antagonism with DON may reduce both cancer growth and stromal barrier production.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts